Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00106
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
3-Nal-Octreotide
|
|||||
| Structure |
|
|||||
| Sequence |
NH2-FC-Nal-WKTCT
|
|||||
| Peptide Type |
Cyclic
|
|||||
| Receptor Name |
Somatostatin receptor type 1 (SSTR1)
|
Receptor Info | ||||
| PDC Transmembrane Types | Cell targeting peptides (CTPs) | |||||
| Formula |
C53H68N10O10S2
|
|||||
| Isosmiles |
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O
|
|||||
| InChI |
InChI=1S/C53H68N10O10S2/c1-30(65)43(27-64)60-52(72)45-29-75-74-28-44(61-47(67)38(55)23-32-13-4-3-5-14-32)51(71)59-41(24-34-17-12-16-33-15-6-7-18-36(33)34)50(70)58-42(25-35-26-56-39-20-9-8-19-37(35)39)49(69)57-40(21-10-11-22-54)48(68)63-46(31(2)66)53(73)62-45/h3-9,12-20,26,30-31,38,40-46,56,64-66H,10-11,21-25,27-29,54-55H2,1-2H3,(H,57,69)(H,58,70)(H,59,71)(H,60,72)(H,61,67)(H,62,73)(H,63,68)/t30-,31-,38-,40+,41+,42-,43-,44+,45+,46+/m1/s1
|
|||||
| InChIKey |
OTPJDZHUIQXBQT-UPUQAJFOSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1069.321
|
Polar area
|
332.22
|
||
|
Complexity
|
1068.45613
|
xlogp Value
|
0.3478
|
|||
|
Heavy Count
|
75
|
Rot Bonds
|
17
|
|||
|
Hbond acc
|
14
|
Hbond Donor
|
13
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
68Ga-DOTANOC [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Neuroendocrine tumour | ||||
| Efficacy Data | Difference in detection ratio |
27.50%
|
|||
| Patients Enrolled |
75 patients with histologically confirmed neuroendocrine tumours and routine clinical.
|
||||
| MOA of PDC |
18F-AlF-OC is noninferior and even superior to 68Ga-DOTATATE/NOC PET in NET patients. This validates 18F-AlF-OC as an option for clinical practice somatostatin receptor PET.
|
||||
| Description |
The resulting mean DDR was 15.8%, with a lower margin of the 95% CI (95% CI, 9.6%-22.0%) higher than -15%, which is the prespecified boundary for noninferiority. The mean DDRs for the 68Ga-DOTATATE and 68Ga-DOTANOC subgroups were 11.8% (95% CI, 4.3-19.3) and 27.5% (95% CI, 17.8-37.1), respectively.
|
||||
References